Drugs / tanCART19/20
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03605238 | Aug 2018 → Aug 2019 | neuromyelitis optica spectrum disorder with anti-AQP4 antibodies | Chinese PLA General Hospital | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tanCART-19/20 | “To assess the safety of the tanCART-19/20 cells in treating NMOSD patients.” NCT03605238 ↗ |
| Action | Deplete | “The investigators infuse tanCART19/20 to completely deplete B cells.” NCT03605238 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor modified T cell infusion” NCT03605238 ↗ |